<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849887</url>
  </required_header>
  <id_info>
    <org_study_id>DR3-07521</org_study_id>
    <nct_id>NCT01849887</nct_id>
  </id_info>
  <brief_title>Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke</brief_title>
  <official_title>Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stroke is a major cause of adult disability. Currently approved reperfusion therapies are&#xD;
      provided to only a small percentage of patients in the U.S. New therapies are needed that&#xD;
      improve outcome and that can be accessed by a majority of patients. Animal studies suggest&#xD;
      that bone marrow-derived mesenchymal stem cells, administered intravenously days after a&#xD;
      stroke, safely improve long-term behavioral outcome. A large human experience suggests the&#xD;
      safety of allogeneic bone marrow-derived mesenchymal stem cells. The current study aims to&#xD;
      assess the safety of this therapy in patients with recent ischemic stroke.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was never started&#xD;
  </why_stopped>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>1 month after transfusion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>bone marrow-derived mesenchymal stem cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bone marrow-derived mesenchymal stem cells</intervention_name>
    <description>bone marrow-derived mesenchymal stem cells</description>
    <arm_group_label>mesenchymal stem cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Ischemic stroke in the middle cerebral artery territory, with onset 24-72 hours&#xD;
             prior to the time that the therapy transfusion is initiated, radiologically confirmed,&#xD;
             and with either diameter &gt;15 mm or volume &gt; 4cc.&#xD;
&#xD;
          -  2. The index stroke has clinical deficits that are moderate-severe (NIHSS score 7-20),&#xD;
             did not require hemicraniectomy or invasive intracranial pressure monitoring, and was&#xD;
             not associated with a concomitant STelevation myocardial infarction.&#xD;
&#xD;
          -  3. Age 18-80 years, inclusive&#xD;
&#xD;
          -  4. Reasonable likelihood of receiving standard post-stroke medical care, as well as&#xD;
             standard physical, occupational, and speech therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. No substantial pre-stroke disability (pre-stroke modified Rankin Scale score 0-2).&#xD;
&#xD;
          -  2. Females of child-bearing potential will be excluded unless (1) a negative urine&#xD;
             pregnancy test is obtained and (2) the patient has been effectively using&#xD;
             contraceptive method with known failure rate &lt;1 % for at least 90 days.&#xD;
&#xD;
          -  3. Lactating mothers&#xD;
&#xD;
          -  4. If thrombolytic therapy has been administered, at least 24 hours have passed&#xD;
             between completing thrombolytic dosing and initiating the current study's transfusion.&#xD;
&#xD;
          -  5. Known allergy to penicillin or to fetal bovine serum&#xD;
&#xD;
          -  6. Active co-existent major neurological or psychiatric disease that could&#xD;
             significantly interfere with patient compliance or study assessments, including drug&#xD;
             or alcohol abuse.&#xD;
&#xD;
          -  7. Any diagnosis that makes survival to 1-year post-stroke unlikely.&#xD;
&#xD;
          -  8. Participation in any other experimental therapeutic clinical trial concurrently or&#xD;
             in the prior three months.&#xD;
&#xD;
          -  9. Contraindication to undergoing MRI scanning.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Cramer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univ Calif Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>May 6, 2013</study_first_submitted>
  <study_first_submitted_qc>May 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>January 20, 2016</last_update_submitted>
  <last_update_submitted_qc>January 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Steven C. Cramer, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

